These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 20814406

  • 1. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices.
    MMWR Morb Mortal Wkly Rep; 2010 Sep 03; 59(34):1102-6. PubMed ID: 20814406
    [Abstract] [Full Text] [Related]

  • 2. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2012 Oct 12; 61(40):816-9. PubMed ID: 23051612
    [Abstract] [Full Text] [Related]

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 Dec 10; 59(RR-11):1-18. PubMed ID: 21150868
    [Abstract] [Full Text] [Related]

  • 4. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 2010 Jul 10; 126(1):186-90. PubMed ID: 20498180
    [Abstract] [Full Text] [Related]

  • 5. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Mar 12; 59(9):258-61. PubMed ID: 20224542
    [Abstract] [Full Text] [Related]

  • 6. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2010 Mar 12; 59(9):253-7. PubMed ID: 20224541
    [Abstract] [Full Text] [Related]

  • 7. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.
    Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.
    Clin Infect Dis; 2006 Jul 15; 43(2):141-50. PubMed ID: 16779739
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH, Stoecker C, Link-Gelles R, Moore MR.
    Vaccine; 2013 Dec 05; 31(50):6011-21. PubMed ID: 24148572
    [Abstract] [Full Text] [Related]

  • 9. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ, Nuorti JP.
    Am J Epidemiol; 2012 Apr 15; 175(8):827-37. PubMed ID: 22403807
    [Abstract] [Full Text] [Related]

  • 10. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices.
    MMWR Recomm Rep; 2000 Oct 06; 49(RR-9):1-35. PubMed ID: 11055835
    [Abstract] [Full Text] [Related]

  • 11. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2012 Jun 01; 61(21):394-5. PubMed ID: 22647745
    [Abstract] [Full Text] [Related]

  • 12. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T.
    MMWR Morb Mortal Wkly Rep; 2015 Sep 04; 64(34):944-7. PubMed ID: 26334788
    [Abstract] [Full Text] [Related]

  • 13. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T.
    MMWR Morb Mortal Wkly Rep; 2019 Nov 22; 68(46):1069-1075. PubMed ID: 31751323
    [Abstract] [Full Text] [Related]

  • 14. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
    Whitney CG.
    Geriatrics; 2003 Oct 22; 58(10):20-2, 25. PubMed ID: 14569639
    [Abstract] [Full Text] [Related]

  • 15. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

  • 16. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.
    Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA.
    Vaccine; 2012 Aug 03; 30(36):5437-44. PubMed ID: 22728289
    [Abstract] [Full Text] [Related]

  • 17. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2008 Feb 15; 57(6):144-8. PubMed ID: 18272956
    [Abstract] [Full Text] [Related]

  • 18. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL, Williams WW, Warnock R, Pilishvili T, Kim D, Kelman JA.
    MMWR Morb Mortal Wkly Rep; 2017 Jul 14; 66(27):728-733. PubMed ID: 28704347
    [Abstract] [Full Text] [Related]

  • 19. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2005 Sep 16; 54(36):893-7. PubMed ID: 16163262
    [Abstract] [Full Text] [Related]

  • 20. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2013 Jun 28; 62(25):521-4. PubMed ID: 23803961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.